{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:14:55Z","timestamp":1792275295798,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T00:00:00Z","timestamp":1490054400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biochem Genet"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s10528-017-9795-8","type":"journal-article","created":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T21:25:15Z","timestamp":1490131515000},"page":"268-277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Sex Differences in the Blood Concentration of Tacrolimus in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients with CYP3A5*3\/*3"],"prefix":"10.1007","volume":"55","author":[{"given":"Ayano","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7521-145X","authenticated-orcid":false,"given":"Tadahiro","family":"Hashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Aomori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiju","family":"Hiromura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Nojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koujirou","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,21]]},"reference":[{"key":"9795_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1089\/jwh.2005.14.19","volume":"14","author":"GD Anderson","year":"2005","unstructured":"Anderson GD (2005) Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenet Pharmacokinet Pharmacodyn J Women\u2019s Health 14:19\u201329. doi: 10.1089\/jwh.2005.14.19","journal-title":"Pharmacogenet Pharmacokinet Pharmacodyn J Women\u2019s Health"},{"key":"9795_CR2","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1681\/ASN.2007121272","volume":"19","author":"H Bao","year":"2008","unstructured":"Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS (2008) Successful treatment of class V\u00a0+\u00a0IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 19:2001\u20132010. doi: 10.1681\/ASN.2007121272","journal-title":"J Am Soc Nephrol"},{"key":"9795_CR3","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.clpt.2006.08.014","volume":"80","author":"M Chen","year":"2006","unstructured":"Chen M, Ma L, Drusano GL, Bertino JS, Nafziger AN (2006) Sex differences in CYP3A activity using intravenous and oral midazolam. Clin Pharmacol Ther 80:531\u2013538. doi: 10.1016\/j.clpt.2006.08.014","journal-title":"Clin Pharmacol Ther"},{"key":"9795_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1124\/dmd.112.046276","volume":"41","author":"SY Choi","year":"2013","unstructured":"Choi SY, Koh KH, Jeong H (2013) Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos 41:263\u2013269. doi: 10.1124\/dmd.112.046276","journal-title":"Drug Metab Dispos"},{"key":"9795_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2165\/00003088-200544010-00002","volume":"44","author":"MM Cotreau","year":"2005","unstructured":"Cotreau MM, von Moltke LL, Greenblatt DJ (2005) The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 44:33\u201360. doi: 10.2165\/00003088-200544010-00002","journal-title":"Clin Pharmacokinet"},{"key":"9795_CR6","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1124\/dmd.105.008680","volume":"34","author":"Y Dai","year":"2006","unstructured":"Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD, Thummel KE (2006) Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 34:836\u2013847","journal-title":"Drug Metab Dispos"},{"key":"9795_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2125.2010.03773.x","volume":"71","author":"U Diczfalusy","year":"2011","unstructured":"Diczfalusy U, Nylen H, Elander P, Bertilsson L (2011) 4beta-Hydroxycholesterol, an endogenous marker of CYP3A4\/5 activity in humans. Br J Clin Pharmacol 71:183\u2013189. doi: 10.1111\/j.1365-2125.2010.03773.x","journal-title":"Br J Clin Pharmacol"},{"key":"9795_CR8","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1177\/0091270008323754","volume":"48","author":"DJ Greenblatt","year":"2008","unstructured":"Greenblatt DJ, von Moltke LL (2008) Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. J Clin Pharmacol 48:1350\u20131355. doi: 10.1177\/0091270008323754","journal-title":"J Clin Pharmacol"},{"key":"9795_CR9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2165\/00003495-199550020-00003","volume":"50","author":"RZ Harris","year":"1995","unstructured":"Harris RZ, Benet LZ, Schwartz JB (1995) Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50:222\u2013239","journal-title":"Drugs"},{"key":"9795_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/FPC.0b013e3283385a1c","volume":"21","author":"LM Hodges","year":"2011","unstructured":"Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE, Altman RB (2011) Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics 21:152\u2013161. doi: 10.1097\/FPC.0b013e3283385a1c","journal-title":"Pharmacogenet Genomics"},{"key":"9795_CR11","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00008571-200112000-00005","volume":"11","author":"E Hustert","year":"2001","unstructured":"Hustert E et al (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773\u2013779","journal-title":"Pharmacogenetics"},{"key":"9795_CR12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2133\/dmpk.22.328","volume":"22","author":"K Iwasaki","year":"2007","unstructured":"Iwasaki K (2007) Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet 22:328\u2013335","journal-title":"Drug Metab Pharmacokinet"},{"key":"9795_CR13","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s10165-011-0425-8","volume":"21","author":"S Kawai","year":"2011","unstructured":"Kawai S, Takeuchi T, Yamamoto K, Tanaka Y, Miyasaka N (2011) Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs\u2013a multicenter, double-blind, parallel-group trial. Mod Rheumatol 21:458\u2013468. doi: 10.1007\/s10165-011-0425-8","journal-title":"Mod Rheumatol"},{"key":"9795_CR14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/86882","volume":"27","author":"P Kuehl","year":"2001","unstructured":"Kuehl P et al (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383\u2013391. doi: 10.1038\/86882","journal-title":"Nat Genet"},{"key":"9795_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/FPC.0b013e328351d47f","volume":"22","author":"J Lamba","year":"2012","unstructured":"Lamba J, Hebert JM, Schuetz EG, Klein TE, Altman RB (2012) PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenet Genomics 22:555\u2013558. doi: 10.1097\/FPC.0b013e328351d47f","journal-title":"Pharmacogenet Genomics"},{"key":"9795_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/bdd.577","volume":"29","author":"LY Miao","year":"2008","unstructured":"Miao LY, Huang CR, Hou JQ, Qian MY (2008) Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. Biopharm Drug Dispos 29:1\u20135. doi: 10.1002\/bdd.577","journal-title":"Biopharm Drug Dispos"},{"key":"9795_CR17","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s10165-009-0218-5","volume":"19","author":"N Miyasaka","year":"2009","unstructured":"Miyasaka N, Kawai S, Hashimoto H (2009) Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod Rheumatol 19:606\u2013615. doi: 10.1007\/s10165-009-0218-5","journal-title":"Mod Rheumatol"},{"key":"9795_CR18","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/bdd.777","volume":"32","author":"H Ohtani","year":"2011","unstructured":"Ohtani H, Barter Z, Minematsu T, Makuuchi M, Sawada Y, Rostami-Hodjegan A (2011) Bottom-up modeling and simulation of tacrolimus clearance: prospective investigation of blood cell distribution, sex and CYP3A5 expression as covariates and assessment of study power. Biopharm Drug Dispos 32:498\u2013506. doi: 10.1002\/bdd.777","journal-title":"Biopharm Drug Dispos"},{"key":"9795_CR19","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/S0021-9258(18)53221-X","volume":"268","author":"T Saeki","year":"1993","unstructured":"Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T (1993) Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 268:6077\u20136080","journal-title":"J Biol Chem"},{"key":"9795_CR20","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00228-010-0869-3","volume":"66","author":"HY Shi","year":"2010","unstructured":"Shi HY et al (2010) Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism. Eur J Clin Pharmacol 66:1131\u20131136. doi: 10.1007\/s00228-010-0869-3","journal-title":"Eur J Clin Pharmacol"},{"key":"9795_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-011-1150-0","author":"P Stratta","year":"2011","unstructured":"Stratta P et al (2011) The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation. Eur J Clin Pharmacol. doi: 10.1007\/s00228-011-1150-0","journal-title":"Eur J Clin Pharmacol"},{"key":"9795_CR22","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/00008571-200208000-00004","volume":"12","author":"K Tang","year":"2002","unstructured":"Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, Lee CG (2002) Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12:437\u2013450","journal-title":"Pharmacogenetics"},{"key":"9795_CR23","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1111\/j.1476-5381.2012.02222.x","volume":"168","author":"C Thangavel","year":"2013","unstructured":"Thangavel C, Boopathi E, Shapiro BH (2013) Inherent sex-dependent regulation of human hepatic CYP3A5. Br J Pharmacol 168:988\u20131000. doi: 10.1111\/j.1476-5381.2012.02222.x","journal-title":"Br J Pharmacol"},{"key":"9795_CR24","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.genm.2012.10.003","volume":"9","author":"R Velickovic-Radovanovic","year":"2012","unstructured":"Velickovic-Radovanovic R, Mikov M, Catic-Djordjevic A, Stefanovic N, Stojanovic M, Jokanovic M, Cvetkovic T (2012) Tacrolimus as a part of immunosuppressive treatment in kidney transplantation patients: sex differences. Gender Med 9:471\u2013480. doi: 10.1016\/j.genm.2012.10.003","journal-title":"Gender Med"},{"key":"9795_CR25","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1053\/jhep.2003.50393","volume":"38","author":"R Wolbold","year":"2003","unstructured":"Wolbold R et al (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38:978\u2013988. doi: 10.1053\/jhep.2003.50393","journal-title":"Hepatology"}],"container-title":["Biochemical Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10528-017-9795-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10528-017-9795-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10528-017-9795-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T19:08:18Z","timestamp":1658862498000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10528-017-9795-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,21]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["9795"],"URL":"https:\/\/doi.org\/10.1007\/s10528-017-9795-8","relation":{},"ISSN":["0006-2928","1573-4927"],"issn-type":[{"value":"0006-2928","type":"print"},{"value":"1573-4927","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,21]]}}}